BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18006806)

  • 21. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management.
    Glinsky GV
    J Clin Oncol; 2008 Jun; 26(17):2846-53. PubMed ID: 18539963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis.
    Balch C; Nephew KP; Huang TH; Bapat SA
    Bioessays; 2007 Sep; 29(9):842-5. PubMed ID: 17688287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon.
    Gandellini P; Folini M; Longoni N; Pennati M; Binda M; Colecchia M; Salvioni R; Supino R; Moretti R; Limonta P; Valdagni R; Daidone MG; Zaffaroni N
    Cancer Res; 2009 Mar; 69(6):2287-95. PubMed ID: 19244118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia.
    Grubach L; Juhl-Christensen C; Rethmeier A; Olesen LH; Aggerholm A; Hokland P; Ostergaard M
    Eur J Haematol; 2008 Aug; 81(2):112-22. PubMed ID: 18410541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the polycomb group proteins in hematopoietic stem cells.
    Konuma T; Oguro H; Iwama A
    Dev Growth Differ; 2010 Aug; 52(6):505-16. PubMed ID: 20646023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and epigenetic alterations in myelodysplastic syndrome.
    Mihara K; Takihara Y; Kimura A
    Cytogenet Genome Res; 2007; 118(2-4):297-303. PubMed ID: 18000383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic gene regulation in cancer.
    Ballestar E; Esteller M
    Adv Genet; 2008; 61():247-67. PubMed ID: 18282509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.
    Kehinde EO; Maghrebi MA; Anim JT
    Can J Urol; 2008 Apr; 15(2):3967-74. PubMed ID: 18405443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stem cell regulation by polycomb repressors: postponing commitment.
    Pietersen AM; van Lohuizen M
    Curr Opin Cell Biol; 2008 Apr; 20(2):201-7. PubMed ID: 18291635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polycomb complexes and epigenetic states.
    Schwartz YB; Pirrotta V
    Curr Opin Cell Biol; 2008 Jun; 20(3):266-73. PubMed ID: 18439810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing of 14-3-3sigma in cancer.
    Lodygin D; Hermeking H
    Semin Cancer Biol; 2006 Jun; 16(3):214-24. PubMed ID: 16698281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic mechanisms in glioblastoma multiforme.
    Nagarajan RP; Costello JF
    Semin Cancer Biol; 2009 Jun; 19(3):188-97. PubMed ID: 19429483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular markers and determinants of prostate cancer metastasis.
    Gopalkrishnan RV; Kang DC; Fisher PB
    J Cell Physiol; 2001 Dec; 189(3):245-56. PubMed ID: 11748582
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors.
    Raaphorst FM
    Hum Mol Genet; 2005 Apr; 14 Spec No 1():R93-R100. PubMed ID: 15809278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of motility proteins and metastasis-suppressor genes in prostate cancer progression.
    Rinker-Schaeffer CW; Chekmareva MA; Mohler JL
    Stem Cells; 1996 Sep; 14(5):508-16. PubMed ID: 8888492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer.
    Gieni RS; Hendzel MJ
    Biochem Cell Biol; 2009 Oct; 87(5):711-46. PubMed ID: 19898523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polycomb-mediated silencing in neuroendocrine prostate cancer.
    Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
    Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genome-wide identification of Polycomb target genes in human embryonic stem cells.
    Xiao X; Li Z; Liu H; Su J; Wang F; Wu X; Liu H; Wu Q; Zhang Y
    Gene; 2013 Apr; 518(2):425-30. PubMed ID: 23313299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer.
    Yu J; Cao Q; Yu J; Wu L; Dallol A; Li J; Chen G; Grasso C; Cao X; Lonigro RJ; Varambally S; Mehra R; Palanisamy N; Wu JY; Latif F; Chinnaiyan AM
    Oncogene; 2010 Sep; 29(39):5370-80. PubMed ID: 20622896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.